Latest Ratios: P/E Ratio -3.7x · EV/EBITDA N/A · ROE -25.3%. (2017–2025 historical series)
Price-based multiples — how expensive the stock is relative to earnings, sales, book value, and cash flow
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Market Cap | $201M | $717M | $291M | $414M | $328M | $626M | $297M | $377M | — | — |
| Enterprise Value | $10M | $525M | $242M | $399M | $306M | $590M | $240M | $280M | — | — |
| P/E Ratio → | -3.72 | — | — | — | — | — | — | — | — | — |
| P/S Ratio | — | — | 3.64 | 147.54 | 51.65 | 32.64 | 33.65 | — | — | — |
| P/B Ratio | 0.68 | 2.05 | 1.20 | 1.76 | 1.65 | 2.96 | 3.12 | 4.33 | — | — |
| P/FCF | — | — | — | — | — | — | — | — | — | — |
| P/OCF | — | — | — | — | — | — | — | — | — | — |
P/E links to full P/E history page with 30-year chart
Enterprise-value multiples — capital-structure-neutral measures of total business value
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| EV / Revenue | — | — | 3.02 | 142.28 | 48.23 | 30.79 | 27.19 | — | — | — |
| EV / EBITDA | — | — | — | — | — | — | — | — | — | — |
| EV / EBIT | — | — | — | — | — | — | — | — | — | — |
| EV / FCF | — | — | — | — | — | — | — | — | — | — |
Margins and return-on-capital ratios measuring operating efficiency
Full margin charts and quarterly trend are on the Earnings History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | — | — | 20.8% | -2459.8% | -1110.7% | -263.7% | -569.2% | — | — | — |
| Operating Margin | — | — | -27.4% | -3945.2% | -1774.9% | -423.0% | -811.6% | — | — | — |
| Net Profit Margin | — | — | -12.2% | -3470.1% | -1732.4% | -421.9% | -802.7% | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| ROE | -25.3% | -25.3% | -4.1% | -44.8% | -53.5% | -52.7% | -77.7% | -101.3% | -84.3% | -1737.1% |
| ROA | -23.9% | -23.9% | -3.8% | -40.2% | -47.6% | -44.4% | -59.0% | -84.3% | -72.3% | -529.1% |
| ROIC | -36.2% | -36.2% | -7.9% | -41.7% | -47.8% | -56.7% | -375.1% | — | -129.7% | -48.6% |
| ROCE | -28.1% | -28.1% | -8.9% | -48.8% | -52.9% | -50.9% | -71.2% | -65.2% | -80.6% | -1478.6% |
Solvency and debt-coverage ratios — lower is generally safer
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Debt / Equity | 0.02 | 0.02 | 0.04 | 0.05 | 0.07 | — | 0.00 | 0.00 | 0.00 | 26.16 |
| Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Net Debt / Equity | — | -0.55 | -0.20 | -0.06 | -0.11 | -0.17 | -0.60 | -1.11 | -0.96 | 25.85 |
| Net Debt / EBITDA | — | — | — | — | — | — | — | — | — | — |
| Debt / FCF | — | — | — | — | — | — | — | — | — | — |
| Interest Coverage | — | — | — | — | — | — | — | — | — | — |
Net cash position: cash ($198M) exceeds total debt ($6M)
Short-term solvency ratios and asset-utilisation metrics
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 27.40 | 27.40 | 22.63 | 17.71 | 12.41 | 11.77 | 4.23 | 8.24 | 17.52 | 0.48 |
| Quick Ratio | 27.40 | 27.40 | 22.63 | 17.71 | 12.41 | 11.80 | 4.33 | 8.00 | 17.39 | 0.22 |
| Cash Ratio | 27.00 | 27.00 | 21.82 | 17.27 | 12.13 | 11.36 | 4.23 | 7.97 | 17.21 | 0.15 |
| Asset Turnover | — | — | 0.31 | 0.01 | 0.03 | 0.08 | 0.07 | — | — | — |
| Inventory Turnover | — | — | — | — | — | — | — | 0.69 | 2.41 | 0.97 |
| Days Sales Outstanding | — | — | 15.25 | 292.65 | 62.21 | 78.28 | 111.99 | — | — | — |
Earnings, FCF, buyback, and dividend yields — total returns to shareholders
Full dividend history and growth charts are on the Dividend History page
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Dividend Yield | — | — | — | — | — | — | — | — | — | — |
| Payout Ratio | — | — | — | — | — | — | — | — | — | — |
| Metric | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 | FY 2019 | FY 2018 | FY 2017 |
|---|---|---|---|---|---|---|---|---|---|---|
| Earnings Yield | — | — | — | — | — | — | — | — | — | — |
| FCF Yield | — | — | — | — | — | — | — | — | — | — |
| Buyback Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Total Shareholder Yield | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | 0.0% | — | — |
| Shares Outstanding | — | $63M | $62M | $61M | $45M | $35M | $25M | $23M | $17M | $17M |
Includes 30+ ratios · 9 years · Updated daily
Live VCP patterns, Cup & Handle overlays, support/resistance, and AI trade plans.
High-probability breakout stocks crossing their pivot across 5 pattern engines.
DCF models, multiple analysis, and analyst estimates.
10-year return with dividends reinvested.
Compare growth, multiples, and margins vs sector.
Quick answers to the most common questions about buying FULC stock.
Fulcrum Therapeutics, Inc.'s current P/E ratio is -3.7x. This places it at the 50th percentile of its historical range.
Fulcrum Therapeutics, Inc.'s return on equity (ROE) is -25.3%. The historical average is -55.5%.
Based on historical data, Fulcrum Therapeutics, Inc. is trading at a P/E of -3.7x. This is at the 50th percentile of its historical P/E range. Compare with industry peers and growth rates for a complete picture.
Key Metrics
Top Statement Risk
Sub-three-quarter cash runway
Metrics are mathematically derived from official filings.
Book Discount Reflects Burn Erosion
Trading at 0.68x book value, Fulcrum appears priced below its stated equity base despite carrying $310.7M in book capital, per recent SEC filings. The -3.18 trailing P/E is an artifact of the lone 2024Q2 milestone, rendering earnings-based valuation inapplicable to this pre-revenue platform.
The 0.68x P/B stands in sharp contrast to peer biotechs in the supplied set — Sarepta at 1.77x, CRISPR Therapeutics at 2.53x, and Arrowhead and Amicus above 16x — which suggests the market is discounting Fulcrum's equity by roughly a third against a peer group that commands premium multiples. That discount may reflect investor pricing of continued dilution risk given the burn rate rather than a view on asset quality, particularly since the balance sheet carries no goodwill or PP&E to anchor liquidation value. EV/EBITDA, EV/Sales and P/FCF are all unavailable across every period, so any multiple triangulation beyond book value rests on incomplete data and warrants further investigation.
Current Ratio Optical Runway Gap
The 31.35 current ratio at 2026Q2 reads as fortress liquidity, yet at the reported ~$16M quarterly operating cash burn that unencumbered cash appears to fund fewer than three quarters, per Fulcrum's filings. The ratio optics and the runway reality diverge materially.
Quick ratio equals current ratio in every period shown, indicating inventory is not a factor — consistent with the near-zero capex and the disappearance of PP&E from the 2026Q2 balance sheet. That parity simplifies the stress test: the entire liquidity question reduces to cash and receivables, and with $48.5M of cash against $13.3M of total liabilities, there is no near-term solvency pressure from obligations. However, applying severe stress — for instance, a delay in milestone timing or an R&D spend re-acceleration — compresses the runway quickly, and investors should monitor whether the equity base drawn down from $349.0M at 2025Q4 to $310.7M at 2026Q2 continues to erode at this pace absent new financing.
Debt Runoff Neutralizes Solvency Risk
Debt-to-equity of 0.02 with total debt amortized down to $5.3M indicates essentially no financial leverage, based on Fulcrum's reported balance sheets. No interest coverage or D/EBITDA data is reported for the recent quarters, so leverage risk appears immaterial relative to the $310.7M equity base.
The debt load has halved from $10.1M in 2024Q1 to $5.3M in 2026Q2, and with equity at $310.7M the company could extinguish remaining obligations several times over from a fraction of its cash. This structural deleveraging means refinancing and covenant risk is essentially absent, which differentiates Fulcrum from leveraged biotech peers such as Amicus at 1.76x D/E or Sarepta at 0.91x. The analytical implication is that the equity story turns entirely on operating cash burn and pipeline optionality rather than capital structure management, so leverage ratios should not be weighted heavily in a credit or distress assessment.
Negative ROIC Defines Operating Trend
ROIC printed negative in nine of ten quarters, bottoming at -11.1% in 2024Q1 and most recently at -5.4% in 2026Q2, per Fulcrum's reported returns data. The solitary 20.7% print coincides entirely with the non-recurring 2024Q2 milestone quarter.
The apparent improvement from -11.1% to -5.4% over the period should not be read as operating leverage, since ROA and ROE have simultaneously widened to -7.8% and -8.1% in 2026Q2; the divergence appears driven by asset base contraction (total assets falling from $366.3M to $324.0M) rather than improving earning power. Because the platform is pre-revenue, the negative ROIC simply reflects the ongoing cash cost of R&D against a shrinking capital base, and no margin-driven or efficiency-driven compounding is observable. Investors should treat the 2024Q2 ROIC print as a statistical outlier rather than a benchmark for sustainable returns, since it traces to the same $80M milestone that distorts every other earnings-based ratio.
Trailing P/E Misread as Cheapness
The -3.18 trailing P/E is the ratio most frequently misapplied to Fulcrum, since it renders a one-time milestone windfall as apparent valuation cheapness. With no recurring revenue and nine of ten loss quarters, earnings multiples obscure rather than illuminate the platform's economics, per recent financial statements.
Negative P/E ratios do not rank cheapness; they simply flag loss-making periods, and FULC's figure is further distorted by an $80M revenue quarter that will not recur unless a new partnership or approval materializes. The more appropriate lenses here are cash-adjusted market capitalization against remaining pipeline assets and the pace of equity erosion — metrics that capture optionality and runway rather than historical earnings that have structurally vanished. Peer comparisons compound the misread: Sarepta at -2.71x and Ultragenyx at -2.95x also screen as "cheap" on negative P/E, yet all three are loss-making platforms whose valuations depend on pipeline catalysts rather than current-period earnings, so a peer-relative P/E ranking carries no analytical signal for this business model.